Skip to main content
. 2008 Oct 9;113(12):2776–2790. doi: 10.1182/blood-2008-06-161018

Figure 7.

Figure 7

NPM-ALK attenuates the effect of methotrexate in lymphoma cells. (A) ATIC enzyme and NPM-ALK kinase were immunoprecipitated from 2 mg of HEK-293T cell lysates and then combined in vitro with increasing concentrations of MTX. Enzymatic activity of total ATIC was measured in vitro. P < .005. (B) ATIC enzyme and NPM-ALK kinase were combined in vitro in the presence of increasing concentrations of MTX and 300 nM of CEP14083 and AICAR-FT activity was measured. *P < .05. (C) CCRF-CEM cells were infected with NPM-ALK or the kinase dead mutant NPM-ALKK210R and treated in culture with increasing concentrations of MTX for 24 hours. Where indicated, the cells were pretreated with 300 nM of CEP14083 for 30 minutes before MTX treatment. AICAR-FT activity was measured. *P < .001, **P < .005.